» Articles » PMID: 33264321

Impact of Disease Stage and Age at Parkinson's Onset on Patients' Primary Concerns: Insights for Targeted Management

Abstract

Background: The concerns of people with Parkinson's disease (PD) about their disease are often different from the objective clinical picture and subject to various influencing factors, including disease progression. Currently our understanding of these concerns is limited, particularly in Asian countries.

Methods: A 50-item survey on Parkinson's Disease Patients' Concerns (PDPC Survey) was developed by a multidisciplinary care team. The subjective greatest concerns (most commonly concerning symptoms) of patients at a specialist centre in Bangkok, Thailand, were explored and categorised according to disease stage and age at onset of PD.

Results: Data for 222 patients showed concerns varied widely. Motor symptoms giving the greatest concern were problems with walking and/or balance (40.5% of patients), while the most commonly concerning non-motor symptom (NMS) was constipation (41.0%). Patterns were observed amongst different patient subgroups. Early PD patients (H&Y stage 1) were more concerned about NMS than motor symptoms, while the reverse was true for advanced PD patients. Young-onset PD patients showed significantly greater concerns than typical-onset patients about motor symptoms relating to social functioning, working and stigmatisation, such as speech (p = 0.003).

Conclusions: This study, in an Asian patient cohort, provides an assessment of a wide range of PD patients' concerns, encompassing not only motor symptoms and NMS, but also treatment-related adverse events, care in the advanced stage, and the need for assistive devices. Identifying the concerns of individual PD patients and implementing a patient-centred approach to care is critical to their wellbeing and optimal outcomes. The PDPC survey can help healthcare teams build a more accurate picture of patients' experiences to inform clinical management.

Citing Articles

User-centred design, validation and clinical testing of an anti-choking mug for people with Parkinson's disease.

Bhidayasiri R, Chaisongkram A, Anan C, Phuenpathom W Sci Rep. 2024; 14(1):14165.

PMID: 38898235 PMC: 11187143. DOI: 10.1038/s41598-024-65071-8.


Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease.

Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte M Mov Disord Clin Pract. 2022; 9(7):869-878.

PMID: 36247919 PMC: 9547138. DOI: 10.1002/mdc3.13523.


Technological evaluation of strategies to get out of bed by people with Parkinson's disease: Insights from multisite wearable sensors.

Sringean J, Thanawattano C, Bhidayasiri R Front Med Technol. 2022; 4:922218.

PMID: 36090600 PMC: 9453393. DOI: 10.3389/fmedt.2022.922218.


Correction: Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management.

Bhidayasiri R, Boonmongkol T, Thongchuam Y, Phumphid S, Kantachadvanich N, Panyakaew P PLoS One. 2021; 16(6):e0252988.

PMID: 34086812 PMC: 8177543. DOI: 10.1371/journal.pone.0252988.

References
1.
Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty I, Deik A, Johnson R . Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism Relat Disord. 2018; 60:118-125. DOI: 10.1016/j.parkreldis.2018.09.005. View

2.
Hattori N, Fujimoto K, Kondo T, Murata M, Stacy M . Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys. Patient Relat Outcome Meas. 2012; 3:31-8. PMC: 3508651. DOI: 10.2147/PROM.S29443. View

3.
Sebring K, Shattuck J, Berk J, Boersma I, Sillau S, Kluger B . Assessing the validity of proxy caregiver reporting for potential palliative care outcome measures in Parkinson's disease. Palliat Med. 2018; 32(9):1522-1528. DOI: 10.1177/0269216318785830. View

4.
Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F . End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol. 2006; 29(6):312-21. DOI: 10.1097/01.WNF.0000232277.68501.08. View

5.
Stacy M . The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm (Vienna). 2010; 117(7):837-46. DOI: 10.1007/s00702-010-0424-5. View